Keith Katkin
CIK 1314596 · PEO;CEO/Urovant Sciences, Inc. · last filed 2026-05-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AVNR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
19800 MACARTHUR BLVD., SUITE 250
IRVINE, CA 92612
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EBS | Director | 111,775 | $6.34 | $708.7K | -$177.6K | 6 | 2026-05-04 |
| SNDX | Director | 124,000 | $13.22 | $1.64M | -$786.1K | 15 | 2026-02-06 |
| ELDN | Director | 8,575 | $2.21 | $19.0K | $0 | 5 | 2026-01-16 |
| RIGL | Director | 2,500 | $49.91 | $124.8K | $0 | 7 | 2021-05-21 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 4 | 2020-09-15 |
| Urovant Sciences Ltd. (UROV) Delisted | PEO;CEO/Urovant Sciences, Inc. | 274,892 | $16.24 | $4.46M | -$1.53M | 7 | 2020-02-21 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | President and CEO | 914,249 | — | — | -$9.20M | 42 | 2014-12-18 |
Recent Filings · Page 2 of 9
89 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-28 | EBS | Grant (A) | +17,430 | $0 | EDGAR |
| 2024-02-09 | SNDX | Grant (A) | +17,000 | $0 | EDGAR |
| 2023-05-30 | EBS | Grant (A) | +33,847 | $0 | EDGAR |
| 2023-05-02 | ELDN | Grant (A) | — | $0 | EDGAR |
| 2023-02-03 | SNDX | Grant (A) | +16,000 | $0 | EDGAR |
| 2023-02-02 | ELDN | Grant (A) | — | $0 | EDGAR |
| 2022-10-07 | SNDX | Mixed | — | -$529.2K | EDGAR |
| 2022-10-04 | SNDX | Mixed | — | -$69.5K | EDGAR |
| 2022-04-05 | EBS | Grant (A) | +8,595 | $0 | EDGAR |
| 2022-02-03 | SNDX | Grant (A) | +16,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.